AVI BioPharma 2003 News Archive
December
-
AVI BioPharma Announces Results From West Nile Virus Clinical Trial
December 30, 2003, Portland, Oregon
-
AVI BioPharma Reports Confirmation of Positive Phase II Clinical Results In Restenosis
December 23, 2003, Portland, Oregon
-
AVI Presents Preclinical Data on Microbubble Drug Delivery And NeuGene Antisense Anti-Cancer Strategies
December 10, 2003, Portland, Oregon
-
AVI BioPharma Antisense Drug Successfully Treats Feline Viral Outbreak
December 4, 2003, Portland, Oregon
-
AVI BioPharma Announces $15 Million Direct Equity Placement
December 4, 2003, Portland, Oregon
November
-
AVI BioPharma Announces Publication of Prostate Cancer Results
November 17, 2003, Portland, Oregon
-
AVI BioPharma Withdraws Proposed Follow-Up Offering
November 14, 2003, Portland, Oregon
-
AVI BioPharma Announces Presentation of Data And Filing for Orphan Designation in Polycystic Kidney Disease
November 13, 2003, Portland, Oregon
-
AVI BioPharma Presents Antisense Antiviral Technology at SMi Conference
November 11, 2003, Portland, Oregon
-
AVI Presents Data on Microbubble Delivery of Restenosis Drug At American Heart Association Annual Meeting
November 6, 2003, Portland, Oregon
-
AVI BioPharma Presents Preclinical Data on Cholesterol-Lowering Program
November 5, 2003, Portland, Oregon
-
AVI BioPharma Announces Third Quarter Financial Results
November 4, 2003, Portland, Oregon
October
-
AVI BioPharma Updates Progress on Infectious Disease Program Using NeuGene Antisense For RNA Viruses
October 29, 2003, Portland, Oregon
-
AVI BioPharma Announces Public Offering of Common Stock
October 29, 2003, Portland, Oregon
-
AVI BioPharma Announces Third Quarter Financial Results Conference Call
October 28, 2003, Portland, Oregon
-
AVI BioPharma CEO to Present at Fifth Annual Rodman & Renshaw Techvest Healthcare Conference
October 20, 2003, Portland, Oregon
-
AVI Initiates Clinical Study to Evaluate the Oral Efficacy of Its NeuGene Antisense Drug
October 10, 2003, Portland, Oregon
-
AVI BioPharma to Initiate Second West Nile Virus Clinical Study With NeuGene Antisense Drug
October 8, 2003, Portland, Oregon
September
-
AVI BioPharma to Present at UBS Global Life Sciences Conferences
September 22, 2003, Portland, Oregon
-
AVI BioPharma Reports Positive Phase II Clinical Results in Restenosis
September 18, 2003, Portland, Oregon
-
AVI BioPharma Begins Clinical Trial of West Nile Virus Patients
September 10, 2003, Portland, Oregon
-
AVI Reports Positive Independent Results With NeuGene Antisense Compound Targeting SARS
September 4, 2003, Portland, Oregon
-
AVI BioPharma Announces Termination of Merger Agreement, Exchange Offer With eXegenics, Inc.
September 2, 2003, Portland, Oregon
August
-
Avi Begins Phase II Study of Systemic Delivery Of Resten-NG in Restenosis
August 19, 2003, Portland, Oregon
-
Avi Files for Orphan Designation for Its SARS Coronavirus Antisense Drug
August 14, 2003, Portland, Oregon
-
Avi BioPharma Announces Increase in Exchange Ratios For eXegenics Capital Stock and Extends Expiration Date to Aug. 29, 2003
August 11, 2003, Portland, Oregon
-
Avi BioPharma Announces Second Quarter Financial Results
August 5, 2003, Portland, Oregon
-
Avi BioPharma Is Cleared to Initiate Clinical Trial for West Nile Virus With NeuGene Antisense Drug
August 4, 2003, Portland, Oregon
July
-
Avi BioPharma Updates Progress on Cardiovascular Disease Program With NeuGene Antisense
July 30, 2003, Portland, Oregon
-
Avi BioPharma and eXegenics Announce Commencement of Exchange Offer For eXegenics Common Stock and eXegenics Preferred Stock
July 29, 2003, Portland, Oregon and Dallas, Texas
-
Avi BioPharma Announces Second Quarter Financial Results Conference Call
July 24, 2003, Portland, Oregon
-
Avi BioPharma Publishes Prostate Cancer Results
July 22, 2003, Portland, Oregon
-
Avi BioPharma to Acquire eXegenics in $11.0 Million Stock Exchange
July 16, 2003, Portland, Oregon and Dallas, Texas
-
Avi BioPharma Presents Positive Results With its Novel Antisense Drug For Prostate Cancer
July 15, 2003, Portland, Oregon
-
Avi BioPharma CEO to Present at International Science Symposium On SARS in China
July 9, 2003, Portland, Oregon
-
Avi BioPharma Manufactures West Nile Virus Antisense Drug
July 7, 2003, Portland, Oregon
-
Avi BioPharma Added to Russell 3000 Index
July 1, 2003, Portland, Oregon
June
May
-
Avi BioPharma Reports Positive Results From NeuGene Cancer Trial
June 19, 2003, Portland, Oregon
-
Avi Files for Orphan Designation for its West Nile Virus Drug
May 14, 2003, Portland, Oregon
-
Dr. Denis Burger's Written Testimony from House Energy and Commerce SARS Hearing
May 7, 2003, Washington D.C.
-
Avi BioPharma to Testify at House Energy and Commerce SARS Hearing
May 6, 2003, Portland, Oregon
-
Avi BioPharma Announces First Quarter Financial Results
May 6, 2003, Portland, Oregon
-
Avi BioPharma Raises $15 Million in Private Placement
May 5, 2003, Portland, Oregon
April
-
Avi BioPharma Announces Presentation on Antiviral Antisense Program
April 29, 2003, Portland, Oregon
-
Avi BioPharma Announces Preclinical Testing Plan For SARS Antisense Compound
April 28, 2003, Portland, Oregon
-
Avi BioPharma Completes West Nile Virus Preclinical Development Program
April 24, 2003, Portland, Oregon
-
Avi BioPharma Presents Data on Systemic Delivery of NeuGene Antisense Drug to Treat Cardiovascular Restenosis
April 2, 2003, Portland, Oregon
March
-
Avi BioPharma Advances NeuGene Antisense Cancer Program
March 26, 2003, Portland, Oregon
-
Avi BioPharma Updates Progress in Single Stranded RNA Viruses With NeuGene Antisense Compounds
March 20, 2003, Portland, Oregon
-
Avi BioPharma Reports Update of NeuGene Antisense Clinical Development Program for 2002, Plans for 2003
March 19, 2003, Portland, Oregon
-
Avi BioPharma Scientist Presents Data Showing Novel Antisense Inhibits Gene Expression of Metabolic Enzyme in Human Liver
March 13, 2003, Portland, Oregon
-
Avi BioPharma Announces 2002 Fourth Quarter And Full Year Financial Results
March 11, 2003, Portland, Oregon
February
January
About AVI BioPharma
Technology
Communication